Cen­tu­ry Ther­a­peu­tics buys Clade; Eliem an­nounces $120M PIPE and a deal

Plus, news about Leap Ther­a­peu­tics, Al­lay Ther­a­peu­tics, Har­mo­ny Bio­sciences, Rally­bio and CSL Behring:

Cen­tu­ry Ther­a­peu­tics ac­quires Clade: Cen­tu­ry is pur­chas­ing the off-the-shelf cell ther­a­py start­up for $35 mil­lion up­front in cash and stock in a deal that comes af­ter Clade laid off em­ploy­ees and closed its Dutch sub­sidiary, as End­points News re­port­ed in Feb­ru­ary. Clade launched with $87 mil­lion in 2021 and was found­ed by CRISPR Ther­a­peu­tics co-founder Chad Cow­an. Cen­tu­ry al­so an­nounced that it’s ex­pand­ing its lead iNK cell ther­a­py in­to au­toim­mune dis­ease, be­gin­ning with a form of lu­pus called SLE, and it raised $60 mil­lion from a pri­vate place­ment in light of the au­toim­mune ex­pan­sion. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER